The recent happenings surrounding Illumina (ILMN) have been dynamic and significant. The company was in the limelight for its new product launches, including the compact, low-cost gene sequencing devices and the MiSeq i100 Series, its simplest and fastest benchtop sequencers. Meanwhile, various investment firms have taken notable positions in Illumina, reflecting its strong momentum as a stock.
Notable overtures have been made by Perpetual Ltd and Partnership Wealth Management LLC. In executive changes, Charles Dadswell has announced his decision to step down as General Counsel, prompting the initiation of a successor search. On another note, the firm has expressed promising financials, with Q2 earnings and revenues topping estimates. However, the company lowered its sales view for 2024.
Notably, Illumina won a jurisdictional appeal at the European Court of Justice. The Board of Directors approved of a spin-off of GRAIL, and the company also won another legal win concerning the Grail deal. However, company shares have been somewhat volatile over the past three years.
There have been advancements in NGS strategies with the DRAGEN v4.3 launch, and the acquisition of Fluent BioSciences aims to accelerate single-cell analysis. Additionally, Illumina has made moves in the domain of oncology, launching a new oncology menu and driving genomic testing as a standard of care.
Illumina ILMN News Analytics from Mon, 05 Feb 2024 08:00:00 GMT to Sat, 12 Oct 2024 22:17:33 GMT - Rating 2 - Innovation 5 - Information 7 - Rumor 1
